Towa Pharmaceutical Co., Ltd. (TWAPF)
- Previous Close
16.83 - Open
16.83 - Bid 18.91 x 40000
- Ask 23.90 x --
- Day's Range
16.83 - 16.83 - 52 Week Range
16.83 - 24.35 - Volume
100 - Avg. Volume
1 - Market Cap (intraday)
1.063B - Beta (5Y Monthly) -0.23
- PE Ratio (TTM)
6.23 - EPS (TTM)
2.70 - Earnings Date Aug 6, 2025 - Aug 12, 2025
- Forward Dividend & Yield 0.54 (3.22%)
- Ex-Dividend Date Sep 29, 2025
- 1y Target Est
--
Towa Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan. The company provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products. It also offers IT service related to healthcare; and disease risk testing services. In addition, the company is involved with research and development of diagnostic drugs; and planning, development and OEM manufacturing of health food, pharmaceuticals, general food and other products. The company was founded in 1951 and is headquartered in Osaka, Japan.
www.towayakuhin.co.jp--
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: TWAPF
View MorePerformance Overview: TWAPF
Trailing total returns as of 5/28/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TWAPF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TWAPF
View MoreValuation Measures
Market Cap
1.06B
Enterprise Value
2.36B
Trailing P/E
6.23
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.46
Price/Book (mrq)
0.69
Enterprise Value/Revenue
1.30
Enterprise Value/EBITDA
7.02
Financial Highlights
Profitability and Income Statement
Profit Margin
7.31%
Return on Assets (ttm)
3.22%
Return on Equity (ttm)
11.59%
Revenue (ttm)
259.59B
Net Income Avi to Common (ttm)
18.99B
Diluted EPS (ttm)
2.70
Balance Sheet and Cash Flow
Total Cash (mrq)
45.47B
Total Debt/Equity (mrq)
137.71%
Levered Free Cash Flow (ttm)
-15.7B